Edgewise Therapeutics Inc (EWTX) Stock Price, Quote & News

Company Profile

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe...

Industry: Biotechnology

Sector: Healthcare

Phone: 720 262 7002

Website: edgewisetx.com

Address:

1715 38th Street, Boulder, United States

GSP Jan. 14 at 10:17 PM

$NVVE $PCT $SERV $EWTX $CRML

0 · Reply

Quantumup Jan. 14 at 1:26 PM

Cantor reiterated $CAPR Overweight-$62 and said, We believe investors are still pricing in regulatory risk for the stock and wouldn't be surprised if shares continue to climb up into a PDUFA date if the package is accepted for review. $EWTX SRPT $DYN $SLDB $PTCT Cantor additionally said, Several have suggested to us that they believe there is still >100% to unlock on an approval. Based on our projections and where the stock is trading today, we estimate the market is factoring in a 25% PoS, which, in our view, is far too low for a company that had positive Phase 3 data in a market where there is clear precedence for strong uptake with new emerging therapies.

1 · Reply

OfficialStocktwitsUser Jan. 14 at 3:05 AM

$EWTX RSI: 63.42, MACD: 0.5530 Vol: 1.65, MA20: 24.00, MA50: 22.73 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Quantumup Jan. 9 at 1:34 PM

Jefferies⬆️ $CYTK's PT to $90 from $80, reiterated at Buy and said, CYTK's upcoming Ph.3 study ACACIA in non-obstructive HCM (nHCM) is one of the biggest readouts in SMID cap biotech in 1H'26. $BMY $EWTX Jefferies went on to say: https://x.com/Quantumup1/status/2009618917161861240?s=20

0 · Reply

JackDarwin Jan. 8 at 12:06 PM

$EWTX Bullish Above the Stomach Candlestick Pattern Formed

0 · Reply

OptionRunners Jan. 7 at 7:57 PM

$EWTX $XBI bunch of biotechs moving higher after the $ABBV $RVMD buyout news

0 · Reply

OptionRunners Jan. 7 at 7:10 PM

$EWTX

0 · Reply

S_Franconi Jan. 6 at 1:21 PM

$EWTX Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 https://investors.edgewisetx.com/news/news-details/2026/Edgewise-Therapeutics-to-Present-at-the-44th-Annual-J-P--Morgan-Healthcare-Conference-on-January-13-2026/default.aspx

0 · Reply

Trainguy1 Jan. 6 at 11:45 AM

$EWTX Who will win this month’s options battle? Max pain is at the $20 strike price, but by far the largest open interest for calls is at the $25 strike price. The largest open interest for puts is at the $19 strike price, but there are quite a few calls and puts at the $20 strike. Based on these numbers, I think the option sellers will hold the stock price between $20 and $25 until Jan 16.

0 · Reply

Trainguy1 Jan. 5 at 12:11 PM

$EWTX - On track to deliver full CIRRUS-HCM 12-week Part D readout in 2Q 2026 - Expect HCM Phase 3 trial to start in 4Q 2026

0 · Reply

Edgewise Therapeutics, Inc. (EWTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 8:00 AM EST - 1 day ago

Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026

Jan 6, 2026, 8:00 AM EST - 8 days ago

Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

Jan 5, 2026, 8:00 AM EST - 9 days ago

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Dec 29, 2025, 2:55 PM EST - 16 days ago

Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst

Dec 26, 2025, 8:12 AM EST - 19 days ago

Why Did Edgewise Therapeutics Jump 25%+ On Wednesday?

Dec 24, 2025, 8:00 AM EST - 21 days ago

Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy

Dec 4, 2025, 3:53 AM EST - 5 weeks ago

Edgewise Therapeutics, Inc. (EWTX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Nov 20, 2025, 8:00 AM EST - 7 weeks ago

Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

Nov 10, 2025, 8:00 AM EST - 2 months ago

Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers

Nov 7, 2025, 8:00 AM EST - 2 months ago

Edgewise Therapeutics to Participate in Upcoming Investor Conferences

Nov 6, 2025, 8:00 AM EST - 2 months ago

Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 2, 2025, 8:00 AM EDT - 3 months ago

Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society

Aug 14, 2025, 3:53 PM EDT - 5 months ago

Edgewise Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Aug 7, 2025, 8:00 AM EDT - 5 months ago

Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 19, 2025, 6:58 PM EDT - 6 months ago

EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Jun 26, 2025, 6:00 AM EDT - 7 months ago

Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies

Jun 3, 2025, 8:00 AM EDT - 8 months ago

Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference

May 14, 2025, 8:00 AM EDT - 8 months ago

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025

May 8, 2025, 8:00 AM EDT - 8 months ago

Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 10, 2025, 6:56 AM EDT - 9 months ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

CAMP

Apr 2, 2025, 4:54 PM EDT - 10 months ago

Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On

Apr 2, 2025, 12:27 PM EDT - 10 months ago

Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study

Apr 2, 2025, 6:22 AM EDT - 10 months ago

Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock

Apr 2, 2025, 6:00 AM EDT - 10 months ago

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)

Mar 26, 2025, 4:45 PM EDT - 10 months ago

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time

Mar 11, 2025, 8:00 AM EDT - 11 months ago

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference

Mar 10, 2025, 1:36 PM EDT - 11 months ago

Edgewise Therapeutics: More Expensive Now, But Much More Derisked

Mar 4, 2025, 8:00 AM EST - 11 months ago

Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025

Mar 3, 2025, 8:00 AM EST - 11 months ago

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Jan 22, 2025, 8:00 AM EST - 1 year ago

Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development

Jan 13, 2025, 8:00 AM EST - 1 year ago

Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025

Jan 7, 2025, 8:00 AM EST - 1 year ago

Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Dec 31, 2024, 2:09 PM EST - 1 year ago

Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data

Dec 16, 2024, 11:56 AM EST - 1 year ago

Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease

Dec 16, 2024, 6:00 AM EST - 1 year ago

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

Dec 5, 2024, 2:32 PM EST - 1 year ago

Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research

Nov 26, 2024, 6:00 AM EST - 1 year ago

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

Sep 30, 2024, 12:12 PM EDT - 1 year ago

Analysts Think There's Still Time To Get In On Edgewise

Sep 25, 2024, 11:50 AM EDT - 1 year ago

Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge

Sep 19, 2024, 10:19 AM EDT - 1 year ago

Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

Sep 17, 2024, 4:01 PM EDT - 1 year ago

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 5, 2024, 2:38 PM EDT - 1 year ago

Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal

GSP Jan. 14 at 10:17 PM

$NVVE $PCT $SERV $EWTX $CRML

0 · Reply

Quantumup Jan. 14 at 1:26 PM

1 · Reply

OfficialStocktwitsUser Jan. 14 at 3:05 AM

0 · Reply

Quantumup Jan. 9 at 1:34 PM

0 · Reply

JackDarwin Jan. 8 at 12:06 PM

$EWTX Bullish Above the Stomach Candlestick Pattern Formed

0 · Reply

OptionRunners Jan. 7 at 7:57 PM

$EWTX $XBI bunch of biotechs moving higher after the $ABBV $RVMD buyout news

0 · Reply

OptionRunners Jan. 7 at 7:10 PM

$EWTX

0 · Reply

S_Franconi Jan. 6 at 1:21 PM

0 · Reply

Trainguy1 Jan. 6 at 11:45 AM

0 · Reply

Trainguy1 Jan. 5 at 12:11 PM

$EWTX - On track to deliver full CIRRUS-HCM 12-week Part D readout in 2Q 2026 - Expect HCM Phase 3 trial to start in 4Q 2026

0 · Reply

mikesterz7 Dec. 26 at 2:28 AM

$EWTX The investigational drug EDG-7500 was generally well tolerated in the trial

0 · Reply

topstockalerts Dec. 25 at 3:26 PM

After Hours Top Gainers PT2 $INDP $SIDU $FMFC $IZM $EWTX

0 · Reply

SharpeRatioS Dec. 25 at 8:37 AM

$EWTX The valuation debate now centers on reliability of delivery, given the heightened sensitivity to timeline slippage. Delivery cadence is becoming the real competitive edge.

0 · Reply

WallStreetBuyDip Dec. 25 at 4:23 AM

Comparing trending tickers $EWTX vs $AGQ: EWTX surged 25.47% to $27.29 on a trading volume of 3.6M shares, significantly above its average of 1.2M. In comparison, AGQ modestly increased by 1.02% to $167.68 with a volume of 3.9M shares, slightly above its usual 2.4M. EWTX is showing more dramatic price movement relative to its volume increase compared to AGQ, which saw less pronounced price changes despite high trading activity.

2 · Reply

WallStreetBuyDip Dec. 25 at 4:02 AM

Comparing trending tickers $D vs $EWTX: "D rose modestly today by 1.50% to $59.01, with trading volume reaching 3.1 million shares, a bit below its average of 5.3 million. In contrast, EWTX surged by 25.47% to $27.29 on a volume of 3.6 million shares, significantly above its usual 1.2 million shares. EWTX's performance today not only shows a substantial price jump but also a dramatic increase in trading activity compared to its norm, outpacing D in both price movement and relative volume spike."

0 · Reply

Ohzipit Dec. 25 at 12:40 AM

$EWTX Raymond James -We Usually Do Gifts in the Evening, but Glad We Opened This One Early; Reiterate Strong Buy

1 · Reply

topstockalerts Dec. 24 at 10:37 PM

Top Gainers PT2 $INDP $SIDU $FMFC $IZM $EWTX

0 · Reply

topstockalerts Dec. 24 at 8:48 PM

After Hours Top Gainers PT2 $INDP $SIDU $FMFC $IZM $EWTX

0 · Reply

AStrokeOfLuck Dec. 24 at 6:45 PM

$EWTX

0 · Reply

topstockalerts Dec. 24 at 6:23 PM

Top Gainers PT2 $INDP $SIDU $FMFC $IZM $EWTX

0 · Reply

topstockalerts Dec. 24 at 5:57 PM

$EWTX heading for a strong close..

0 · Reply

StocktwitsNews Dec. 24 at 5:25 PM

Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease — Wall Street Eyes A Potential Standout $EWTX $IWMW $AVUS https://stocktwits.com/news/equity/markets/edgewise-therapeutics-stock-jumps-after-trial-update-for-genetic-heart-disease/cLetbZlREvN

2 · Reply

Market Cap	2.55B
Revenue (ttm)	0.00
Net Income (ttm)	-133.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,390,705
Avg Vol	1,507,634
Day's Range	N/A - N/A
Shares Out	105.87M
Stochastic %K	83%
Beta	0.27
Analysts	Strong Sell
Price Target	$38.17